Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors Refractory to Standard Therapy”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Early research (Phase 1)Study completedNCT04026321
What this trial is testing

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Who this might be right for
Solid Tumor Refractory to Standard Therapy
Livzon Pharmaceutical Group Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT07309770
What this trial is testing

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Who this might be right for
Urachal CancerAdvanced Solid Tumor CancerAntibody-drug Conjugates
Sheng Zhang 90
Early research (Phase 1)Temporarily pausedNCT03120130
What this trial is testing

Study of Amblyomin-X in Advanced Solid Tumor

Who this might be right for
Advanced Cancer
União Química Farmacêutica Nacional S/A 24
Early research (Phase 1)Ended earlyNCT00089089
What this trial is testing

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Who this might be right for
Hematopoietic/Lymphoid CancerUnspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 42
Early research (Phase 1)Study completedNCT00741234
What this trial is testing

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Who this might be right for
Solid TumorsHematologic MalignanciesMyelodysplastic Syndrome
S*BIO 85
Early research (Phase 1)Active Not RecruitingNCT02112565
What this trial is testing

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
City of Hope Medical Center 12
Early research (Phase 1)Study completedNCT01288989
What this trial is testing

Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Who this might be right for
Neoplasms
Eli Lilly and Company 44
Early research (Phase 1)Study completedNCT02690337
What this trial is testing

Study of DS-1123a in Advanced Solid Tumours

Who this might be right for
Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd. 27
Testing effectiveness (Phase 2)Ended earlyNCT00001880
What this trial is testing

Stem Cell Transplantation for Metastatic Solid Tumors

Who this might be right for
Neoplasm Metastasis
National Heart, Lung, and Blood Institute (NHLBI) 42
Early research (Phase 1)Study completedNCT00968981
What this trial is testing

Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 67
Early research (Phase 1)Study completedNCT00914914
What this trial is testing

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

Who this might be right for
Refractory Solid Tumors
Dr. Tapas K. Das Gupta 15
Early research (Phase 1)Study completedNCT00816361
What this trial is testing

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Who this might be right for
Cancer
MedImmune LLC 43
Testing effectiveness (Phase 2)UnknownNCT04640246
What this trial is testing

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Who this might be right for
CancerTumor, SolidRefractory Cancer
Taiga Biotechnologies, Inc. 60
Early research (Phase 1)Study completedNCT00878423
What this trial is testing

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Who this might be right for
Metastatic Solid Tumors
Astex Pharmaceuticals, Inc. 62
Early research (Phase 1)Ended earlyNCT02508441
What this trial is testing

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Who this might be right for
Advanced Unresectable Solid Tumors
Andes Biotechnologies 22
Early research (Phase 1)UnknownNCT05989724
What this trial is testing

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorBreast CancerPancreatic Cancer+2 more
Qurgen Inc. 150
Testing effectiveness (Phase 2)Study completedNCT01253837
What this trial is testing

L19TNFα in Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorsColorectal Cancer
Philogen S.p.A. 34
Testing effectiveness (Phase 2)Study completedNCT01949688
What this trial is testing

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Who this might be right for
Solid Tumors
Shiga University 26
Large-scale testing (Phase 3)Study completedNCT00666211
What this trial is testing

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
Vanderbilt-Ingram Cancer Center 98
Early research (Phase 1)Study completedNCT03985072
What this trial is testing

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Who this might be right for
Tumor, SolidGall Bladder CancerCervical Cancer+3 more
Andes Biotechnologies 67
Next Page